Popular Articles

C. elegans Poster Award Recipients Announced By Genetics Society Of America
The Genetics Society of America is pleased to announce the recipients for the first place poster awards from the 17th International C. elegans meeting held June 24-28 at the University of California, Los Angeles. Eighteen posters from among the 375 graduate posters reviewed by the selection committee were selected for the first award of $55 (US).

First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University Of Wisconsin Riverview Cancer Center
Earlier this month the University of Wisconsin Cancer Center Riverview became the first medical facility in the world to treat patients with a breakthrough treatment of skin cancer. Located within Riverview Hospital, Wisconsin Rapids, the UW Cancer Center Riverview is the first to treat skin cancer patients with the FDA-cleared Axxent(R) Electronic Brachytherapy System from Xoft, Inc. Electronic Brachytherapy, eBx(TM) , delivers a high therapeutic dose to a cancer tumor while sparing nearby normal tissue by using a miniaturized X-ray rather than radioactive isotopes.
News of the day
Delays To Seeing Docs Stretch On
A new study finds the average wait for a medical appointment has increased by more than a week since 2004, to 8.6 days, USA Today reports. In Boston, the worst-performing city of the 15 surveyed for the Merritt Hawkins and Associates study, patients waited nearly 50 days, on average, to see a doctor.
Health Insurance

All Fifty States To Screen Newborns For Cystic Fibrosis By 2010

The Cystic Fibrosis Foundation announced today that all 50 states, plus the District of Columbia, have passed legislation requiring that all newborns be screened for cystic fibrosis (CF) by the year 2010. Early diagnosis of cystic fibrosis, a life-threatening, genetic disease, can have a dramatic impact on the health of those born with the condition. Newborn screening for CF was adopted nationwide at a rapid pace, following the aggressive advocacy efforts of the Cystic Fibrosis Foundation, its volunteers and many local and national interest groups. In 2005, only five states required that CF be included on the list of mandatory screening conditions. After years of debate, Texas and Connecticut - the last two states without mandatory newborn screening - will now establish programs. Connecticut will begin screening Oct. 1, 2009, and Texas is expected to start in December. "We congratulate Texas and Connecticut for joining a nationwide effort to ensure that every child born with cystic fibrosis gets the best possible start in life," said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. "Newborn screening is critically important for this disease because early diagnosis is tied to better health. We extend our thanks to every volunteer and advocate who fought to establish screening programs across the country." Research shows that newborn screening for CF likely improves and extends the lives of those born with the disease. Early diagnosis allows affected infants to begin therapeutic interventions immediately. Early treatment has been shown to improve height, weight, nutrition, cognitive and lung functioning, and to reduce hospitalizations. Cystic fibrosis affects approximately 30,000 children and adults in the United States and 70,000 people worldwide. It causes thick mucus to build up in the lungs and other organs, resulting in life-threatening infections and serious digestive complications. More than 10 million Americans are symptomless carriers of a cystic fibrosis gene. Most people who have a child with CF are not aware of a family history of the disease. When the Cystic Fibrosis Foundation was created in 1955, few children lived to attend elementary school. Today, as a result of dramatic improvements in research and care fueled by the Foundation, the median age of survival for a person with CF is more than 37 years. Cystic Fibrosis Foundation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):